Miragen Therapeutics announced incremental new data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in adult T-cell leukemia/lymphoma, or ATLL, in an oral presentation at the International Congress HTLV. Previously published data suggest that patients with aggressive forms of ATLL typically succumb to their disease within 4-10 months on average from the time of diagnosis. In updated data from the cobomarsen Phase 1 trial, five patients with an aggressive ATLL subtype in partial remission have been treated with cobomarsen for up to 16 months. Four of five patients remained stable for up to 16 months and continue on the trial. Biological activity of cobomarsen in these subjects is indicated by a significant decrease in biomarkers of cell proliferation and activation in all patients, supporting the observed clinical stabilization. Cobomarsen has been well tolerated over prolonged treatment, with no deaths, DLTs, related serious adverse events, related Grade 3 or Grade 4 adverse events, hematological events or discontinuation from trial due to related adverse events.
https://thefly.com/landingPageNews.php?id=2898293
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.